Next generation sequencing (NGS) on EBUS-TBNA has a higher yield for detecting clinically relevant mutations in NSCLC than liquid biopsy alone.
Liquid biopsy identifies unique mutations not captured by tissue sampling, underscoring its complementary diagnostic role.
The combined use of EBUS-TBNA and liquid biopsy enhances comprehensive genomic profiling but requires optimization of turnaround time and insufficient quantity sample (QNS) criteria.
